Triton BioSystems Inc.
http://www.tritonbiosystems.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Triton BioSystems Inc.
Deal Watch: Bristol, Janssen Keep The Heat High In Cancer Immunotherapy Deal-Making
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.
Nanobiotix SA
Nanobiotix is taking advantage of the ability of nanoparticles to absorb and transform energy to treat cancer. The company's nanoXray technology uses standard x-ray to activate injected cell-targeting non-drug nanoparticles. Today, Nanobiotix is focused solely on cancer applications of its technology, but the company believes there are other targets for the technology, including cardiovascular diseases.
Start-Up Previews (4/06)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, What Nanotech Means to Health Care Investors, features profiles of Keystone Nano, Mersana Therapeutics, Nanotrope and Triton BioSystems. Plus these Start-Up Across Health Care: Biowave, MediWound, OrthoHelix Surgical Designs and TheraPei Pharmaceuticals.
What Nanotech Means to Health Care Investors
If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice